JHL Biotech, Inc. announced that the first group of subjects has been randomized and dosed last week in the company's Australian Phase I Clinical Trial of JHL1266 in healthy subjects. The Three-Arm Study is randomized, double-blinded, parallel-grouped, and single-dosed and will compare the pharmacokinetic similarity of JHL1266 versus Prolia sourced from the EU and the US in healthy human subjects. It is one of the pivotal studies for registration with the ultimate objective to evaluate the similarity in Pharmacokinetics (PK), Pharmacodynamics (PD), and immunogenicity. JHL1266, a proposed biosimilar to denosumab, is a monoclonal antibody targeting RANKL and works by inhibiting the development of osteoclasts and then preventing break down of bones in the human body. The targeted indications include the treatment of osteoporosis, bone metastases, giant cell tumors of bone, and other treatment-induced bone loss.